NetworkNewsBreaks – Zenosense, Inc. (ZENO) Targe
Post# of 53
(Total Views: 135)
Posted On: 04/27/2018 6:36:23 PM
NetworkNewsBreaks – Zenosense, Inc. (ZENO) Targets Global POC Market with MIDS Cardiac Device
Healthcare technology company Zenosense (OTC: ZENO) is well positioned to capitalize on the projected growth in the global point-of-care (“POC”) diagnostics market, forecast to grow at a CAGR of 10 percent, from $23.71 billion in 2017 to $38.13 billion in 2022 according to a recent Research and Markets report (http://nnw.fm/o0fNq), through the development and commercialization of its MIDS Cardiac device. An article discussing the company reads: “MIDS’ key differentiator is its unique ability to detect and measure these assay beads by their total aggregated nano-magnetic signal, rather than conventional optical detection. Initial testing has demonstrated that this novel approach should enable MML to develop a highly sensitive, accurate, miniaturized device to support high-sensitivity cardiac biomarker testing. Such a POC device could be used in the emergency room, a doctor’s office, the bedside and by paramedics in emergency situations, such as in an ambulance.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Healthcare technology company Zenosense (OTC: ZENO) is well positioned to capitalize on the projected growth in the global point-of-care (“POC”) diagnostics market, forecast to grow at a CAGR of 10 percent, from $23.71 billion in 2017 to $38.13 billion in 2022 according to a recent Research and Markets report (http://nnw.fm/o0fNq), through the development and commercialization of its MIDS Cardiac device. An article discussing the company reads: “MIDS’ key differentiator is its unique ability to detect and measure these assay beads by their total aggregated nano-magnetic signal, rather than conventional optical detection. Initial testing has demonstrated that this novel approach should enable MML to develop a highly sensitive, accurate, miniaturized device to support high-sensitivity cardiac biomarker testing. Such a POC device could be used in the emergency room, a doctor’s office, the bedside and by paramedics in emergency situations, such as in an ambulance.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Zenosense Inc. (ZENO) Stock Research Links
Scroll down for more posts ▼